SciELO - Scientific Electronic Library Online

 
vol.104 issue2Is safety infliximab during pregnancy in patients with inflammatory bowel disease?Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Española de Enfermedades Digestivas

Print version ISSN 1130-0108

Abstract

CERQUETELLA, Matteo et al. Efficacy of an enterovaccine in recurrent episodes of diarrhea in the dog: a pilot study. Rev. esp. enferm. dig. [online]. 2012, vol.104, n.2, pp.65-68. ISSN 1130-0108.  http://dx.doi.org/10.4321/S1130-01082012000200004.

Recurrent episodes of self-limiting diarrhea in the dog, due to sudden dietary changes and to stressful or exciting situations, are conditions sometimes difficult to treat. Colifagina®, a commercially available bacterial enterovaccine, showed, in previous studies performed on experimentally induced colitis in mice, to be able to improve both disease activity index and histological appearance, increase colonic secretion of IgA, and reduce inflammatory chemokine secretion. In the present study Colifagina® was administered to five dogs presenting recurrent episodes of self-limiting diarrhea and to one dog presenting chronic diarrhea. During the follow-up period, almost all patients decreased the number of episodes of abnormal defecation and the fecal score of such episodes improved in five out of six dogs. Even if further studies are needed to understand the exact potential of the compound, in dogs presenting recurrent episodes of self-limiting diarrhea due to sudden dietary changes and/or stressing or exciting situations, Colifagina® seems to be helpful in managing most of these patients.

Keywords : Diarrhea; Dogs; Enterovaccine; Treatment.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License